Application of wogonin in preparation of drug for treating hepatic fibrosis

A technology of wogonin and liver fibrosis, applied in the field of pharmaceuticals, can solve the problems of prevention and treatment of liver fibrosis that have not been reported yet, achieve the effect of alleviating liver fibrosis, and have a wide application prospect

Inactive Publication Date: 2019-03-08
ANHUI MEDICAL UNIV
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Previous studies have shown that wogonin has a wide range of biological activities, such as anti-inflammation, anti-oxidation, anti-tumor, anti-virus, and neuroprotective effects, among which anti-tumor activity is one of the hotspots of research at home and abroad, but has not been reported yet. It has the effect of preventing and treating liver fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of wogonin in preparation of drug for treating hepatic fibrosis
  • Application of wogonin in preparation of drug for treating hepatic fibrosis
  • Application of wogonin in preparation of drug for treating hepatic fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1: Wogonin (Wog) induces recombinant human collagen-1 (Collagen-α) to transforming growth factor (TGF-β) in vitro 1 ), α-smooth muscle actin (α-SMA) and hepatic stellate cells (HSC)

[0026] Stellate cells (HSC) T6 in the logarithmic growth phase were seeded in 6-well plates and 12-well plates at a seeding density of about 1.0×10 5 cells / ml, divided into normal group (NC, control), model group (TGF-β, model) and wogonin group (TGF-β+Wog), each group repeated 3-4 experiments, incubated for 24 hours 10ng / ml TGF-β was added to the model group and wogonin group, and 1.25μg / ml Wog was added to the wogonin group. After continuing to culture for 24 hours, the cells were washed three times with PBS, the cells were collected, and the total protein and RNA.

[0027] Detect liver fibrosis index protein (Collagen-α) by Western Blot and Real time-PCR according to the method provided 1 and α-SMA) expression. The result is as figure 1 As shown, it shows that wogonin ca...

Embodiment 2

[0029] Embodiment 2: Wogonin on aspartate aminotransferase (AST), alanine aminotransferase (ALT), Collagen-α in liver fibrosis model rats 1 and the effect of α-SMA

[0030] The 6-8 week-old C57BL / 6 mice were adaptively cultured for 1-2 days, and divided into normal group (NC), model group (CCl 4 ), wogonin low dose group (CCl 4 +Wog 10mg / kg), middle dose group (CCl 4 +Wog 20mg / kg), high dose group (CCl 4 +Wog40mg / kg), 12-16 in each group. Intraperitoneal injection of 20% CCl in the model group and low, medium and high dose groups of wogonin 4 2.5ml / kg to establish liver fibrosis model, and intraperitoneally inject 10mg / kg, 20mg / kg and 40mg / kg Wog to rats in low, medium and high dose groups of wogonin, respectively, and culture for 6 weeks.

[0031] Under anesthesia, the serum samples and liver tissues of the mice cultured for 6 weeks were taken, and after the liver tissues were embedded and sectioned, they were stained with HE (hematoxylin-sosin staining) to detect liver d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of wogonin in preparation of a drug for treating hepatic fibrosis. The application has the advantages that the application of the wogonin in preparation of the drugfor treating hepatic fibrosis is disclosed for the first time; the wogonin has the effects of effectively inhibiting the expression of an index protein of hepatic fibrosis in vitro, promoting the expression of an apoptosis index protein in HSC(hepatic stellate cells) and reducing the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase and the expression of Collagen-alpha 1and alpha-SMA, therefore, the wogonin has the effect of relieving hepatic fibrosis, the mechanism of action of the wogonin is related to the effect of prompting the apoptosis of the HSC, the wogoninis wide in application prospect, and more drug choices are also provided for treatment of hepatic fibrosis.

Description

technical field [0001] The invention belongs to the field of pharmacy, and more specifically relates to the new application of wogonin in the preparation of medicines for treating liver fibrosis. Background technique [0002] Hepatic fibrosis (Hepatic fibrosis, HF) is a common clinical liver disease. It is a compensatory response in the process of tissue repair after liver inflammation or injury caused by various pathogenic factors. As a result of deposition, its continued development can lead to cirrhosis and even liver cancer. The activation of hepatic stellate cells (hepatic stellate cells, HSC) is the central link leading to HF, so far there is no effective treatment for HF, therefore, it is necessary to look for treatments that can reduce tissue damage, inhibit HSC activation, promote HSC apoptosis, and prevent liver cirrhosis. , the hepatoprotective drugs in the occurrence of liver cancer are of great significance. [0003] The molecular formula of Wogonin (Wog) is C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P1/16
CPCA61K31/352A61P1/16
Inventor 李俊孟晓明李海迪杜潇洒姜玲徐节节黄成
Owner ANHUI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap